T cell receptor alpha constantGenealiases: IMD7 · TCRA · TRCA
Q-omics provides the consensus-scored TRAC profile across patient tissues and cancer cell-line models. TRAC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAC is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TRAC RNA expression shows 18,182 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TRAC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAC survival associations across molecular data types. TRAC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAC RNA expression–survival associations across cancer types. High TRAC expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, CESC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAC RNA expression.
This table summarizes TRAC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAC shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, STAD, BRCA and LIHC. The KIRC box plot shows higher TRAC RNA expression in tumor versus normal tissue (log2 FC = +2.003, t-test p < 0.001).
This table shows molecular features associated with TRAC in patient tissues and cancer cell lines. In patient samples, TRAC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
